A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
Not applicable
Completed
88
2026-01
Industry sponsor intelligence
KalVista Pharmaceuticals, Ltd.Clinical Pipeline.
Lead-sponsor view of KalVista Pharmaceuticals, Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 0
Pipeline overview
Programs by phase and activity.
Velocity
KalVista Pharmaceuticals, Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Icatibant → | 1 | 0 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All KalVista Pharmaceuticals, Ltd. studies.
This page groups studies where KalVista Pharmaceuticals, Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates